Picture of Ironwood Pharmaceuticals logo

IRWD — Ironwood Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Ironwood Pharmaceuticals Inc expected to post earnings of 26cents a share - Earnings Preview

* Ironwood Pharmaceuticals Inc  IRWD.OQ   IRWD.O  is
expected
to show a rise in quarterly revenue when it reports  results on
November 3. 
    * The Boston Massachusetts-based  company is expected to
report  a
5.2% increase in revenue to $109.106 million from $103.75
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ironwood
Pharmaceuticals
Inc is for earnings of 26 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $14​, above​ its last closing price
of $10.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  0.30        0.30       0.21      Missed  -28.8
 Mar. 31 2022  0.25        0.26       0.21      Missed  -17.6
 Dec. 31 2021  0.36        0.35       0.27      Missed  -23.6​
 Sep. 30 2021  0.31        0.31       0.33      Beat    6.5
 ​​Jun.        0.23        0.23       0.34      Beat    47.8
 30 2021                                                
 Mar. 31 2021  0.22        0.21       0.24      Beat    16.5​
 Dec. 31 2020  0.29        0.29       0.36      Beat    24.8
 Sep. 30 2020  0.15        0.15       0.23      Beat    51.3
 This summary was machine generated November 1 at 13:12 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Ironwood Pharmaceuticals

See all news